Thus, our identification of the role of Sur8 as a critical mediator of metastasis in human cancer through the regulation of both the PI3K-Akt and Ras-ERK pathways introduces Sur8 as a potential therapeutic target for the development of anti-cancer drugs to control tumor metastasis that arises from activated Ras and PI3K signaling. Here, AKT1 is linked to neoplasm.